Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Peter Hartung

Showing results (51-60 of 601) with videos related to

Pageof 61
Sort By:
Journal of the Neurological Sciences|March 30, 2007
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosisOliver Neuhaus, Bernd C Kieseier, Hans-Peter Hartung
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2014
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosisHans-Peter Hartung, Orhan Aktas, Alexey N Boyko
Journal of Neural Transmission (Vienna, Austria : 1996)|June 25, 2013
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazardsClemens Warnke, Bernd C Kieseier, Hans-Peter Hartung
Nature Reviews. Neurology|June 17, 2010
Fingolimod is a potential novel therapy for multiple sclerosisOrhan Aktas, Patrick Küry, Bernd Kieseier, et al.
Neurology|December 25, 2002
Immune mechanisms in chronic inflammatory demyelinating neuropathyBernd C Kieseier, Marinos C Dalakas, Hans-Peter Hartung
Current Opinion in Neurology|April 16, 2019
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigmBruce A C Cree, Jan Mares, Hans-Peter Hartung
Current Opinion in Neurology|June 8, 2022
New drugs for multiple sclerosis: new treatment algorithmsBruce A C Cree, Hans-Peter Hartung, Michael Barnett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
Monoclonal Antibodies for Multiple Sclerosis: An UpdateJonas Graf, Orhan Aktas, Konrad Rejdak, et al.
Current Opinion in Neurology|January 30, 2019
Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspectsMichael Dietrich, Orhan Aktas, Hans-Peter Hartung, et al.
Cell Cycle (Georgetown, Tex.)|September 5, 2008
p57 kip2's role beyond Schwann cell cycle controlAndré Heinen, David Kremer, Hans-Peter Hartung, et al.
Pageof 61

Showing results (51-60 of 601) with videos related to

Sort By:
Pageof 61
Journal of the Neurological Sciences|March 30, 2007
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosisOliver Neuhaus, Bernd C Kieseier, Hans-Peter Hartung
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 26, 2014
Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosisHans-Peter Hartung, Orhan Aktas, Alexey N Boyko
Journal of Neural Transmission (Vienna, Austria : 1996)|June 25, 2013
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazardsClemens Warnke, Bernd C Kieseier, Hans-Peter Hartung
Nature Reviews. Neurology|June 17, 2010
Fingolimod is a potential novel therapy for multiple sclerosisOrhan Aktas, Patrick Küry, Bernd Kieseier, et al.
Neurology|December 25, 2002
Immune mechanisms in chronic inflammatory demyelinating neuropathyBernd C Kieseier, Marinos C Dalakas, Hans-Peter Hartung
Current Opinion in Neurology|April 16, 2019
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigmBruce A C Cree, Jan Mares, Hans-Peter Hartung
Current Opinion in Neurology|June 8, 2022
New drugs for multiple sclerosis: new treatment algorithmsBruce A C Cree, Hans-Peter Hartung, Michael Barnett
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 4, 2019
Monoclonal Antibodies for Multiple Sclerosis: An UpdateJonas Graf, Orhan Aktas, Konrad Rejdak, et al.
Current Opinion in Neurology|January 30, 2019
Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspectsMichael Dietrich, Orhan Aktas, Hans-Peter Hartung, et al.
Cell Cycle (Georgetown, Tex.)|September 5, 2008
p57 kip2's role beyond Schwann cell cycle controlAndré Heinen, David Kremer, Hans-Peter Hartung, et al.
Pageof 61